TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

T. L. Lasho; A. Tefferi; J. D. Hood; S. Verstovsek; D. G. Gilliland; A. Pardanani

doi:10.1038/leu.2008.56

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

T. L. Lasho, A. Tefferi, J. D. Hood, S. Verstovsek, D. G. Gilliland, A. Pardanani

Leukemia

Research output: Contribution to journal › Article › peer-review

97 Scopus citations

Original language	English (US)
Pages (from-to)	1790-1792
Number of pages	3
Journal	Leukemia
Volume	22
Issue number	9
DOIs	https://doi.org/10.1038/leu.2008.56
State	Published - 2008

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2008.56

Cite this

Lasho, T. L., Tefferi, A., Hood, J. D., Verstovsek, S., Gilliland, D. G., & Pardanani, A. (2008). TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia, 22(9), 1790-1792. https://doi.org/10.1038/leu.2008.56

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. / Lasho, T. L.; Tefferi, A.; Hood, J. D. et al.
In: Leukemia, Vol. 22, No. 9, 2008, p. 1790-1792.

Research output: Contribution to journal › Article › peer-review

Lasho, TL, Tefferi, A, Hood, JD, Verstovsek, S, Gilliland, DG & Pardanani, A 2008, 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients', Leukemia, vol. 22, no. 9, pp. 1790-1792. https://doi.org/10.1038/leu.2008.56

@article{678453d6adda4945a94b045316ab87d5,

title = "TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients",

author = "Lasho, {T. L.} and A. Tefferi and Hood, {J. D.} and S. Verstovsek and Gilliland, {D. G.} and A. Pardanani",

note = "Funding Information: John Hood is an employee and shareholder of TargeGen Inc. This work was supported by a research grant from TargeGen Inc. and from the Myeloproliferative Disorders Foundation, Chicago, IL, USA. Funding Information: This work was supported by the Abraham J & Phyllis Katz Foundation and Donald J & Ruth Weber Goodman Philanthropic Fund.",

year = "2008",

doi = "10.1038/leu.2008.56",

language = "English (US)",

volume = "22",

pages = "1790--1792",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

AU - Lasho, T. L.

AU - Tefferi, A.

AU - Hood, J. D.

AU - Verstovsek, S.

AU - Gilliland, D. G.

AU - Pardanani, A.

N1 - Funding Information: John Hood is an employee and shareholder of TargeGen Inc. This work was supported by a research grant from TargeGen Inc. and from the Myeloproliferative Disorders Foundation, Chicago, IL, USA. Funding Information: This work was supported by the Abraham J & Phyllis Katz Foundation and Donald J & Ruth Weber Goodman Philanthropic Fund.

PY - 2008

Y1 - 2008

UR - http://www.scopus.com/inward/record.url?scp=49449100990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449100990&partnerID=8YFLogxK

U2 - 10.1038/leu.2008.56

DO - 10.1038/leu.2008.56

M3 - Article

C2 - 18354492

AN - SCOPUS:49449100990

SN - 0887-6924

VL - 22

SP - 1790

EP - 1792

JO - Leukemia

JF - Leukemia

IS - 9

ER -

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this